Bioceltech Therapeutics, Ltd. is a high-tech company which focuses on the development and application of new technology in immunotherapy. It is located in the key planning gathering area of Bio-High-Tech industry -- PKUCare Industrial Park, Zhongguancun Life Science Park, Beijing.
The core technology team consists of many senior immunotherapy experts from the University of Pennsylvania, Harvard University and other famous American immunotherapy centers and enterprises. They have engaged in the research and development, quality control, standardized production and clinical application management of immunotherapy such as CAR-T for nearly 20 years.
The team has cooperated with the Institute Of Hematology, Peking University People's Hospital since 2016 and together we successfully cured a 3-year-old patient with Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) by using HLA-haploidentical allogenic CAR-T cell therapy (T-cells of the patient's relatives).
umor biological therapy is a new approach of tumor therapy with remarkable curative effect, and it is a novel method of autoimmune anticancer treatment.
The inspection and evaluation of immune function are important for clinical guidance and monitoring, either for patients who receiving immunotherapy or for sub-health and normal people who receiving immune cell health care.
Recently，immunosenscence is becoming one of the hot topic in the research field of basic immunology and immunotherapy
Stem cells, with the potential of self-renewal and multi-directional differentiation, are the original cells of the organism. They can form various tissues and organs of human body. Under certain conditions, it can differentiate into many functional cells、tissue and organs. It is called “Universal cell” in medical field.
（CAR-T technology is a developed adoptive cell therapy in recent years, and it is recognized as a unique way to completely conquer human cancers. In August 2011, the American Journal of Bio-Translational Medicine and the New England Journal of Medicine reported that professor?Carl H. June, who is a gene therapist at the University of Pennsylvania, had cured two patients with Advanced Chronic Lymphoblastic Leukemia (CLL) by using a modified autologous T-cell (CAR-T).
